Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey - Top-Institutions - MDSpire

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey

  • By

  • Niklas Schäfer

  • Elisabeth Bumes

  • Fabian Eberle

  • Viola Fox

  • Florian Gessler

  • Frank A. Giordano

  • Juergen Konczalla

  • Julia Onken

  • Malte Ottenhausen

  • Moritz Scherer

  • Matthias Schneider

  • Hartmut Vatter

  • Ulrich Herrlinger

  • Patrick Schuss

  • June 11, 2021

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Medical Oncology
    • Radiation Oncology

  • #2

    Dana-Farber/Brigham and Women's Cancer Center
    Dana-Farber/Brigham and Women's Cancer Center

    Boston, MA

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Medical Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Radiation Oncology
    • Medical Oncology

  • #4

    University Hospital Heidelberg
    University Hospital Heidelberg

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Medical Oncology
    • Radiation Oncology

  • #5

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Neuro-Oncology
    • Neurosurgery
    • Medical Oncology

Original Source(s)

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey

  • by Niklas Schäfer, Elisabeth Bumes, Fabian Eberle, Viola Fox, Florian Gessler, Frank A. Giordano, Juergen Konczalla, Julia Onken, Malte Ottenhausen, Moritz Scherer, Matthias Schneider, Hartmut Vatter, Ulrich Herrlinger, Patrick Schuss

  • June 11, 2021

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Potential targets for boron transport in boron neutron capture therapy